Mike Ferris, our Associate Director, Operations is excited to attend this year's EMIM conference. He is looking forward to connecting with fellow experts, exchange insights, and dive into the latest advancements in immuno-oncology and further discuss theranostics, including noninvasive imaging techniques that are revolutionizing how we approach cancer diagnosis and treatment.
Additionally, there are two oral presentations and three posters featuring, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) that will be featured at this year's conference.
If you’re attending, don’t miss the chance to connect with Mike and learn more about our lead investigational imaging agent, CD8 ImmunoPET and learn how it's being used in clinical trials.